Bard Receives Approval For The Revolutionary New TELESCOPE Angioplasty Catheter
MURRAY HILL, NJ--(BUSINESS WIRE)--December 23, 1997--C.R. Bard, Inc. (NYSE-BCR) today announced it has received U.S. Food and Drug Administration clearance to market the revolutionary new TELESCOPE(TM) Single Operator over-the-wire balloon catheter.
The TELESCOPE balloon catheter is the first fully interchangeable, single operator angioplasty device to combine over-the-wire performance with a standard length guidewire. This technologically superior TELESCOPE catheter revolutionizes PTCA catheter shaft design by providing the interventional cardiologist with a totally new level of flexibility and versatility.
As its name suggests, the unique shaft of the TELESCOPE catheter is constructed from telescoping segments, allowing the physician to swiftly and easily shorten or lengthen the catheter according to the requirements of the procedure. In addition, the TELESCOPE catheter offers a patented anti-backbleed and wirelock system which minimizes blood loss during the PTCA procedure. The TELESCOPE catheter also features Bard's unique patented Rely(R) balloon material which is widely recognized for its superior performance during difficult multi-lesion cases.
``Since our pioneering work in balloon angioplasty in the 1970s, our research engineers have continually strived to provide the interventional cardiologist with new and innovative devices to treat coronary artery disease. Now they have reached a new level of achievement with the TELESCOPE catheter system,'' commented William H. Longfield, Bard's chairman and chief executive officer.
``This unique catheter provides not only flexibility and ease of use, but also the potential to substantially reduce the balloons required and cost per procedure.'' Bard plans to launch the TELESCOPE catheter in the U.S. market in early 1998, where several patents currently limit the cardiologists' choice in single operator systems. Bard will continue to supply its markets outside the U.S. with its latest generations of over-the-wire and rapid exchange catheters. The TELESCOPE will eventually be launched worldwide when production volumes permit.
ANy comments as the the potential impact of this catheter. Is this a novel new approach? Will it meet any unmet needs? How will it be received?